3MO - First-line camrelizumab plus carboplatin and paclitaxel for advanced squamous non-small cell lung cancer: Updated overall survival results from the phase III CameL-sq trial (ID 241)
4MO - Final overall survival (OS) data of sintilimab plus pemetrexed (SPP) and platinum as first-line (1L) treatment for locally advanced or metastatic nonsquamous NSCLC (AMnsqNSCLC) in the phase III ORIENT-11 study (ID 242)
4MO - III 期 ORIENT-11 研究:信迪利单抗+培美曲塞 (SPP)+铂类一线治疗疗局部晚期或转移性非鳞状 NSCLC的最终OS数据(ID 242)
6MO - Pembrolizumab plus ipilimumab or placebo in previously untreated metastatic NSCLC with PD-L1 tumor proportion score ≥50%: KEYNOTE-598 3-year follow-up (ID 244)
6MO – 帕博利珠单抗+伊匹木单抗或安慰剂治疗初治PD-L1肿瘤比例评分(TPS)≥50%转移性 NSCLC:KEYNOTE-598研究3年随访结果 (ID 244)
7MO - Oritinib (SH-1028) a third-generation EGFR tyrosine kinase inhibitor in locally advanced or metastatic NSCLC patients with positive EGFR T790M: Results of a single-arm phase II trial (ID 247)
7MO - 第三代 EGFR TKI奥瑞替尼(Oritinib,SH-1028)在EGFR T790M 阳性局部晚期或转移性NSCLC的疗效:一项单臂 II 期试验结果 (ID 247)
1O - Furmonertinib versus gefitinib in treatment-na?ve EGFR mutated non-small cell lung cancer: A randomized, double-blind, multi-center, phase III study (FURLONG) (ID 223)
1O – 伏美替尼 vs 吉非替尼在初治 EGFR 突变NSCLC患者中的疗效和安全性:一项多中心、III 期随机双盲研究 (FURLONG) (ID 223)
80O - Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: Sub-analysis from the pivotal phase III IMpower010 study (ID 226)